CPDA

Cat. No.: HY-18685

CAS No.: 1415834-63-7

Molecular Formula: $C_{20}H_{15}ClF_2N_2O_2$

Molecular Weight: 388.8

Target: Phosphatase

Pathway: Metabolic Enzyme/Protease

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 50 mg/mL (128.60 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.5720 mL	12.8601 mL	25.7202 mL
5 mM	0.5144 mL	2.5720 mL	5.1440 mL
10 mM	0.2572 mL	1.2860 mL	2.5720 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (6.43 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (6.43 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

CPDA is a novel potent SH2 domain-containing inositol phosphatase 2 (SHIP2) inhibitor.

IC_{50} & Target

SHIP2

In Vitro

CPDA enhances insulin signaling.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

CPDA greatly improves abnormal glucose metabolism in diabetic animals. CPDA improves the abnormal glucose metabolism in db/db mice.

	MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). Eur J Med Chem. 2013 Apr;62:649-660.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA